A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?
复制标题

DOI:
10.1517/14656566.2010.493558
复制
发表时间:
2010-07
影响因子:
3.2
通讯作者:
Lapchak PA
Lapchak PA
中科院分区:
医学3区
文献类型:
--
作者:
Lapchak PA

文献摘要

参考文献

被引文献

相似文献

依达拉奉(Radicut®)是三菱Tanabe制药公司在日本销售的一种自由基清除剂,用于治疗发病24小时内出现的急性缺血性中风(AIS)患者。注射用依达拉奉安瓶(30毫克,每天2次,静脉注射,14天)于2001年5月23日首次获得批准。2010年1月19日,作为一项新的创新,Radicut袋获得了日本厚生福利省的批准。依达拉奉的疗效范围从大幅显着的临床改善到在缺血性中风后6-72小时使用标准中风评分表衡量的临床功能仅有轻微改善。依达拉奉有近17年的临床经验,已注意到包括急性肾功能衰竭在内的一些不良事件。这是迄今为止唯一一篇对文献中发表的现有临床疗效和毒理学数据进行批判性审查的文章,以确定是否应该进一步将依达拉奉作为全球开发的候选药物。本综述涵盖了1993-2008年间进行的临床研究。依达拉奉可能是一种有用的神经保护剂,每年治疗全球1500多万中风患者。还需要进行更多的临床研究来验证依达拉奉的疗效。
Edaravone (Radicut®) is a free radical scavenger marketed in Japan by Mitsubishi Tanabe Pharma Corporation to treat acute ischemic stroke (AIS) patients presenting within 24 hours of the attack. Injectable edaravone ampoules (30mg b.i.d, i.v., 14 days) were first approved on May 23, 2001. On January 19th 2010, as a new innovation, the Radicut BAG was approved by the Japanese Ministry of Health and Welfare. Efficacy of edaravone range from large significant clinical improvements to only modest improvements in clinical function measured using standard stroke scales when administered 6–72 hours following an ischemic stroke. With almost 17 years of edaravone clinical experience, a few adverse events including acute renal failure have been noted. This is the only article to date to critically review available clinical efficacy and toxicology data published in the literature to ascertain whether edaravone should be further pursued as a candidate for development worldwide. This review covers clinical studies done during the periods 1993–2008. Edaravone may a useful neuroprotective agent to treat more than 15 million worldwide victims devastated by stroke annually. Additional clinical studies are necessary to verify the efficacy of edaravone.
DOI: 10.1016/j.ejphar.2005.04.036
发表时间: 2005-06-01
影响因子: 5
作者:
Amemiya, S;Kamiya, T;Katayama, Y
通讯作者: Katayama, Y
DOI: 10.1056/nejmoa0804656
发表时间: 2008-09-25
影响因子: 158.5
作者:
Hacke, Werner;Kaste, Markku;Toni, Danilo
通讯作者: Toni, Danilo
DOI: 10.1001/archneur.1996.00550040037012
发表时间: 1996-04-01
影响因子: --
作者:
Hacke, W;Schwab, S;vonKummer, R
通讯作者: vonKummer, R
DOI: 10.1046/j.1525-1373.1999.d01-140.x
发表时间: 1999-12-01
影响因子: --
作者:
Floyd, RA
通讯作者: Floyd, RA
DOI: 10.2169/internalmedicine.45.1423
发表时间: 2006-01-01
期刊: INTERNAL MEDICINE
影响因子: 1.2
作者:
Inatomi, Yuichiro;Takita, Tomohiro;Uchino, Makoto
通讯作者: Uchino, Makoto